Lipoquin

May 16, 2016May 16, 2016

Aradigm’s Candidates for NCFBE Featured at ATS 2016

The American Thoracic Society (ATS) is hosting the ATS 2016 International Conference through May 18 in San Francisco, Calif. Aradigm, an emerging pharmaceutical focused on drugs for the prevention and ... Read more

September 11, 2015October 28, 2015

Study Shows Aradigm’s Lipoquin and Pulmaquin As Promising Therapies for Treatment of Pulmonary NTM

News, Pneumonia

In a poster communication that will be presented on September 19, 2015 at the International Congress of Chemotherapy and Infection (ICAAC/ICC 2015) in San Diego, CA, entitled “Treatment of Lung Infection Caused ... Read more

May 14, 2015November 6, 2015

Researchers Report Encouraging Results in Treating Pulmonary Non-Tuberculous Mycobacteria With Liposomal Ciprofloxacin

Bronchiectasis, News

Researchers at Oregon State University, Corvallis (OSU) and pharmaceutical company Aradigm Corporation have found that Aradigm’s investigational products Lipoquin® and Pulmaquin® are capable of significantly reducing the growth of the ... Read more